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GCs by histopathology is high, however. The aim of this study was to demonstrate the feasibility of gene
profiling as a new diagnostic method in clinical practice, namely in a large cohort of patients suffering
from acute cardiac decompensation. Methods and Results: In this retrospective multicenter study, EMBs
taken from n = 427 patients with clinically acute cardiac decompensation and suspected acute myocardi-
tis were screened (mean age: 47.03 ± 15.69 years). In each patient, the EMBs were analyzed on the basis
of histology, immunohistology, molecular virology, and gene-expression profiling. Out of the total of n
= 427 patient samples examined, GCs could be detected in 26 cases (6.1%) by histology. An established
myocardial gene profile consisting of 27 genes was revealed; this was narrowed down to a specified profile
of five genes (CPT1, CCL20, CCR5, CCR6, TLR8) which serve to identify histologically proven IGCM
with high specificity in 25 of the 26 patients (96.2%). Once this newly established profiling approach was
applied to the remaining patient samples, an additional n = 31 patients (7.3%) could be identified as
having IGCM without any histologic proof of myocardial GCs. In a subgroup analysis, patients diagnosed
with IGCM using this gene profiling respond in a similar fashion to immunosuppressive therapy as pa-
tients diagnosed with IGCM by conventional histology alone. Conclusions: Myocardial gene-expression
profiling is a promising new method in clinical practice, one which can predict IGCM even in the absence
of any direct histologic proof of GCs in EMB sections. Gene profiling is of great clinical relevance in terms
of a) overcoming the sampling error associated with purely histologic examinations and b) monitoring
the effectiveness of therapy.
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Abstract: Aims: The diagnostic approach to idiopathic giant-cell myocarditis (IGCM) is based on identifying
various patterns of inflammatory cell infiltration and multinucleated giant cells (GCs) in histologic sections
taken from endomyocardial biopsies (EMBs). The sampling error for detecting focally located GCs by
histopathology is high, however. The aim of this study was to demonstrate the feasibility of gene profiling
as a new diagnostic method in clinical practice, namely in a large cohort of patients suffering from acute
cardiac decompensation. Methods and Results: In this retrospective multicenter study, EMBs taken from
n = 427 patients with clinically acute cardiac decompensation and suspected acute myocarditis were
screened (mean age: 47.03± 15.69 years). In each patient, the EMBs were analyzed on the basis of histology,
immunohistology, molecular virology, and gene-expression profiling. Out of the total of n = 427 patient
samples examined, GCs could be detected in 26 cases (6.1%) by histology. An established myocardial
gene profile consisting of 27 genes was revealed; this was narrowed down to a specified profile of five
genes (CPT1, CCL20, CCR5, CCR6, TLR8) which serve to identify histologically proven IGCM with high
specificity in 25 of the 26 patients (96.2%). Once this newly established profiling approach was applied
to the remaining patient samples, an additional n = 31 patients (7.3%) could be identified as having
IGCM without any histologic proof of myocardial GCs. In a subgroup analysis, patients diagnosed with
IGCM using this gene profiling respond in a similar fashion to immunosuppressive therapy as patients
diagnosed with IGCM by conventional histology alone. Conclusions: Myocardial gene-expression profiling
is a promising new method in clinical practice, one which can predict IGCM even in the absence of any
direct histologic proof of GCs in EMB sections. Gene profiling is of great clinical relevance in terms of
(a) overcoming the sampling error associated with purely histologic examinations and (b) monitoring the
effectiveness of therapy.
Keywords: idiopathic giant-cell myocarditis; gene-expression profiling; endomyocardial biopsy
1. Introduction
Cardiac inflammatory processes involving giant cells comprise a diverse group of disorders [1–4]
Idiopathic giant-cell myocarditis (IGCM) is regarded as a distinct clinical and pathological entity having
an exclusively cardiac manifestation. This rapidly progressive disease is associated with myocyte
necrosis and poor cardiac outcome [5,6]. IGCM has been shown to involve multinucleated giant cells
(GCs) which have thus far been discovered mainly in lymphocytic infiltrates and among myocytolytic
tissue and eosinophils [7–9]. Since GCs tend to be focally distributed within endomyocardial biopsies
(EMBs), their presence is very often missed by conventional histologic evaluation due to the sampling
error involved. Thus, the actual incidence of IGCM could well be higher than its detection rate. The earlier
IGCM is diagnosed and immunosuppressive treatment is initiated, the better the patient recovers, given
that permanent myocardial damage can be prevented (or at least minimized), thereby improving the
prognosis and possibly avoiding the need for heart transplantation. Recently published studies have
shown [10,11] that myocardial gene-expression profiling defines a distinct gene expression pattern
which serves to indicate the presence of IGCM even without any histologic detection of GCs. Generally
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speaking, specific gene-expression profiles describe the time-specific and disease-specific synthesis
of cytokines and adhesion molecules, thereby defining the activation states of pro-inflammatory and
anti-inflammatory intracellular pathways [12–14]. Thus, gene-expression profiling has recently been
assumed to play an increasingly important diagnostic role for rejection surveillance after cardiac
transplantations [15–17]. Given the focal infiltration pattern which GCs exhibit in cardiac tissue, novel
methods for diagnosing IGCM are urgently needed. This multicenter study addresses the clinical
evaluation of gene profiling for purposes of identifying patients afflicted with IGCM. The aim of
this study was (a) the identification of a distinct gene-profiling, (b) to demonstrate the feasibility of
gene profiling in clinical practice within a large cohort of patients, and (c) to show the efficacy of
subsequently applied immunosuppressive treatment regarding the prognosis of the disease.
2. Patients and Methods
2.1. Patients
This retrospective multicenter study evaluated the EMB specimens of n= 427 patients suffering from
clinically unexplained acute decompensation; these specimens had been sent to the IKDT (Institute for
Cardiac Diagnostic and Therapy Berlin, Germany). Analysis included histology, immunohistochemistry,
molecular virology, and gene profiling. The suspected clinical diagnoses had been made by clinicians
at the relevant medical centers. In order to develop gene-expression profile that could serve as a
novel tool for the diagnosis of GCs, twenty-three age-matched and gender-matched patients without
intramyocardial inflammation or viral infection were used as a peer group to create the control-group
profiles. They were referred for evaluation of repeated chest discomfort but had no symptoms of heart
failure. Patient characteristic and hemodynamic data are summarized in Table 1 (see also Supplemental
Data Table S1 for EMB results).
Table 1. Control Group Patient Characteristics and Echocardiographical Data.
n 23
Age (years) 48.5 ± 12.9
LVEF (%) 51.5 ± 15.4
LVEDD (mm) 55.5 ± 9.3
TAPSE (mm) 23 ± 4.1
IVSD (mm) 11.8 ± 3.1
LVPW (mm) 11.2 ± 2.8
Note: LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; TAPSE = tricuspid
annular plane systolic excursion; IVSD = intraventricular septum diameter; LVPW = left ventricular posterior wall.
The data are presented as mean ± standard deviation, and as No. (%) of subjects.
2.2. Analysis of Myocardial Morphology and Inflammation
Histologic evaluations were performed on paraffin sections of two to three EMBs using standard
procedures, e.g., formaldehyde or RNAlater fixation, paraffin embedding, staining with hematoxylin and
eosin, elastic van Gieson stain (EvG) and Azan stain. The EMB diagnosis of active myocarditis was based on
the histomorphologic criteria according to the Dallas Classification [18]. Immunohistochemistry was used
to characterize the inflammatory infiltrates and was carried out on RNAlater-fixed samples (two EMBs).
Myocardial inflammation was diagnosed by CD3+ T-lymphocytes/mm2 (Dako, Glostrup, Denmark),
CD11a+/LFA-1+ lymphocytes/mm2 (Immuno Tools, Friesoythe, Germany), CD11b+/Mac-1+macrophages/
mm2 (ImmunoTools), CD45R0+ T memory cells (Dako, Glostrup, Denmark), perforin+ cytotoxic cells/mm2
(BD Bioscience, San Jose, CA, USA). Inflammatory cells were quantified using quantitative digital-imaging
analysis, reported elsewhere [19]. Intramyocardial inflammation was categorized according to the ESC
Statement [20]. We also analysed macrophages (threshold >40.0 CD11b+/Mac-1+ macrophages/mm2),
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CD45R0+ T Memory cells (threshold > 40 cells/mm2), and perforin-positive cytotoxic cells (threshold >
2.9 cells/mm2).
2.3. Nucleic Acid Isolation, Reverse Transcription (RT) and nPCR for cDNA
Genomic DNA from two to three EMBs was extracted using Puregene Core Kit A (Qiagen,
Hilden, Germany). Total RNAs were isolated during routine EMB diagnostics using Trizol reagent
(Thermo Fisher Scientific, Waltham, MA, USA); these were treated with DNAse (PeqLab, Erlangen,
Germany) to remove any traces of genomic DNA and were then reverse-transcribed to cDNA with
the High Capacity Kit (Thermo Fisher Scientific) using random hexamer primers. DNA and cDNA
concentrations were quantified using the PCR-based Quantifiler™Human DNA Quantification Kit
(Thermo Fisher Scientific).
2.4. Preamplification and Gene-Expression Analysis
Given the limited amounts of extracted myocardial cDNA available, a gene-specific PCR-based
pre-amplification technique was applied. Gene expression was then determined via qPCR amplification
of generated preAMP-DNA. The expression level was calculated in relation to the housekeeping
gene HPRT while applying the Delta-Delta-Ct method [21]. All predesigned gene-expression qPCR
assays were purchased from Thermo Fisher Scientific and applied in keeping with the manufacturer’s
instructions. To ensure the technical integrity of the gene profile test, samples that produced low
amounts of RNA were excluded from further analysis. The cut-off values were set at Ct < 25 for HPRT
detection and for QuantifilerTM analysis, respectively. Samples of each patient were run in parallel with
HPRT for quantification of mRNA and internal assay amplification control to ensure standardization
of PCR. Previous in vivo and in vitro microarray-based studies had identified a set of 27 genes that
have been shown to be deregulated by inflammatory cardiomyopathy. These genes serve as coding
for cellular receptors or immune-response mediators, or are part of energy metabolism pathways [11]
(Table S2). The evaluation of the myocardial gene-expression profiles revealed a specific expression
pattern encompassing five specific genes: chemokine receptor 5 (CCR5), chemokine receptor 6 (CCR6);
carnitine palmitoyltransferase I (CPT1), toll-like receptor 8 (TLR8), and chemokine (C-C motif) ligand
20 (CCL20) [22–27]. Expression of CPT1 was found to be downregulated in IGCM.
2.5. Statistics
The quantitative results of the analysis were expressed as mean ± SD (standard deviation) values.
The parametric paired t-test was used to analyze data within a group, whereas the parametric unpaired
t-test was used to compare different groups. Once it had been established that none of the data were
distributed normally, the non-parametric Mann-Whitney U test for group comparisons and Wilcoxon’s
signed rank test for comparisons between baseline and follow-up were utilized. The non-parametric
Spearman correlation method was used for correlation analysis. P-values below 0.05 were treated
as indicators of statistical significance. All statistical analyses were performed using Version 23.0 of
the SPSS software, (IBM Corp. Armonk, NY, USA), as well as the GraphPad Prism 7.04 software
(GraphPad Software Inc., La Jolla, CA, USA).
3. Results
The patients included in this study were evaluated by means of extensive EMB analysis, including
histologic, immunohistochemical, molecular virology analyses and gene profiling. A summary overview of
the patients’ characteristics, hemodynamic data and suspected clinical diagnoses can be found in Table 2.
In n = 26 patients, the incidence of IGCM could be determined through histopathologic analyses
of EMBs. All the patients included in this study were considered for purposes of establishing the
specific gene-expression profile.
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Histology-proven IGCM was found to be present in n = 26 patients. In this patient group, n = 23
patients fulfilled the criteria for active myocarditis according to the Dallas Classification; in the
remaining n = 3 patients, borderline cases of myocarditis were indicated.
Table 2. Patients’ Characteristics, Hemodynamic Data and Suspected Clinical Diagnoses within the
Entire Study Group.
Patient Data Entire Cohort
n 427
Age (years) 47.03 ± 15.69
LVEF (%) 38.54 ± 17.89
LVEDD (mm) 54.51 ± 8.75
TAPSE (mm) 22.40 ± 5.93
IVSD (mm) 11.31 ± 2.80
LVPW (mm) 10.84 ± 2.40
NYHA I/II/III/VI (n) 0/0/250/177





- cardiac sarcoidosis 20
- unexplained acute heart failure 86
Note: LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; TAPSE = tricuspid
annular plane systolic excursion; IVSD = intraventricular septum diameter; LVPW = left ventricular posterior
wall; NYHA = New York Heart Association Classification; AMC = acute myocarditis; IGCM = idiopathic giant
cell myocarditis; DCMi = dilated inflammatory cardiomyopathy; EOM = eosinophilic myocarditis; The data are
presented as mean ± standard deviation, or as No. of subjects (No., n).
Representative images of the histologic and immunohistologic findings are shown in Figure 1.
Figure 1. Representative Histologic and Immunohistochemical Images. Images (A) & (B): Patients
with normal myocardium; i.e., no CD3 stain (A) and no Mac1 stain (B). Images (C) & (D): Patients with
IGCM presenting GCs surrounded by diffuse infiltration of massively increased T lymphocytes (CD3)
(C) and macrophages (Mac1) in immunohistologic staining (D). Image (E): EvG staining from a patient
with severe active myocarditis and giant cells. Magnification ×200.
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3.1. Distinctive Myocardial Gene-Expression Profiles Which Serve to Identify IGCM
EMBs taken from the 26 patients with histologically confirmed IGCM were analyzed. The gene-
expression profile could be used to successfully identify histologically proven IGCM with a high degree
of specificity in 25 of the 26 patients (96.2%) (Figure 2, Figure S1, Table S3).
Figure 2. Gene-expression profiles for IGCM patients (n = 26) in relation to inflammation-negative
patients/control cohort (n = 23). The figure shows a distinct gene-expression pattern with high statistical
significance, as derived from the unpaired t-test. P-values are denoted by asterisks: ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001.
3.2. Application of IGCM-Specific Gene Profiling across the Entire Cohort of Patients with Acute
Cardiac Decompensation
As a next step, the gene-expression data of the remaining patients (n = 401) who exhibited
acute cardiac decompensation but no histologically detected GCs were evaluated based on the new
numeric thresholds of the five genes identified for the IGCM-specific gene profile. When this newly
derived profiling was applied, an additional n = 31 patients could be identified as having a distinctive
gene-expression pattern suggestive of IGCM; these patients were therefore classified as suspected
cases of IGCM despite the absence of histologic proof for the presence of myocardial GCs.
In particular, a gene profile matching the criteria for multinucleated giant cells could be observed
in n = 14 of the patients with clinically suspected acute myocarditis. In n = 10 of the patients presenting
a positive gene profile for GCs, an inflammatory cardiomyopathy had been clinically suspected; in n = 7
patients, unexplained acute heart failure had been diagnosed (Figure 3). Out of these 31 patients,
an evaluation of EMBs determined that n = 6 patients actually had active myocarditis according to the
Dallas Classification based on histology. In the remaining n = 25 patients, borderline myocarditis was
identified (Figure 3).
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Figure 3. Clinically Suspected Diagnoses and IGCM Histologically Proven or Detected by Gene-Profiling.
Note: AMC= acute myocarditis; IGCM= idiopathic giant cell myocarditis; DCMi=dilated inflammatory
cardiomyopathy; EOM = eosinophilic myocarditis.
Including samples taken from the 427 patients suffering from acute cardiac decompensation,
multinucleated giant cells were ultimately detected in a total of 26 (6.1%) of the patients by means of
histology. However, based on the improved diagnostics offered by myocardial gene profiling, an additional
n = 31 patients of the remaining cohort could also be identified as having giant cells even without any
direct histologic proof of such cells. Thus, out of the overall cohort of 427 patients with acute cardiac
decompensation, a total of 57 patients (13.3%) could be diagnosed as having IGCM. Only 26 of these 57
(45.6%) had a histologic presentation of GCs. In other words, n = 31 of those 57 (54.4%) would have been
overlooked if conventional histology alone had been used.
3.3. Immunohistologic Analysis of Intramyocardial Infiltration in GCM Patients
When it comes to the immunohistologic staining found among the IGCM patient samples,
the number of infiltrative cells involved ranges widely. See Table 3 for a breakdown of IGCM diagnoses
based on conventional, histologic proof and those based on gene profiling.
3.4. Correlation of Immunohistochemical Markers with Deregulated Genes
In the total patient cohort, gene-expression data for the five deregulated genes in the IGCM-specific
profile were correlated with the number of digitally measured immune cell numbers in the cardiac EMBs.
Analysis revealed a weak correlation between Mac-1+ macrophages and CD45R0+ T memory-cells on
the one hand and the computed IGCM-specific gene-profile score on the other (p ≤ 0.05; r = 0.158 and
r = 0.161). For CD3+ lymphocytes, perforin+ cytotoxic cells, and LFA-1+ lymphocytes, no correlation
was observed (n.s.; r = 0.090, r = 0.048 and r = 0.042) (see Supplemental Data Figure S2).
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Table 3. Immunohistologic EMB Analysis of Intramyocardial Infiltration in GCM Patients Based on
Conventional Histology or on Gene Profiling.
Patient Data IGCM (By Histology) IGCM (By Gene Profiling)
Immunohistology
- CD3+ lymphocytes infiltration/mm2 312.4 ± 297.3 125.8 ± 196.3 *
- LFA-1+ lymphocytes infiltration/mm2 462.6 ± 413.8 183.4 ± 215.0 *
- CD45R0+ T memory cell infiltration/mm2 533.3 ± 349.6 114.9 ± 502.3 *
- perforin+ cell infiltration/mm2 16.23 ± 26.00 14.14 ± 32.23
- Mac-1+ macrophages infiltration/mm2 428.8 ± 344.0 181.1 ± 227.1 *
Note: Immunohistologic marker: CD3 = T-lymphocytes; LFA-1 = leukocyte function antigen-1; Mac-1 =macrophage-1
antigen; CD45R0 (UCHL1) = leucocyte common antigen; perforin = cytotoxic cells. The data are presented as mean ±
standard deviation. Asterisk (*) indicates significant variance between the incidence of IGCM derived from histology
and that derived from gene profiling.
3.5. EMB-Based Diagnosis Out of The Entire Study Group
See Supplemental Table S4 for the EMB-based diagnostic findings for the entire study group.
3.6. Clinical and Hemodynamic Outcome of IGCM Patients at Follow-Up after Immunosuppressive Treatment
In a subgroup analysis we evaluated the response of patients with gene-profiling diagnosis of
IGCM to immunosuppressive therapy. Therefore, we evaluated the observed, clinical hemodynamic
outcome at follow-up (mean follow-up time: 6.4 ± 4.3 months) in patients who had received immediate
immunosuppressive therapy as well as heart-failure medication after receiving an EMB-based diagnosis
of IGCM. In the process, the clinical outcomes were compared between those patients whose IGCM had
been histologically confirmed (n = 17) and those whose ICGM had been diagnosed by gene profiling
(n = 23) (Table 4).
Table 4. Clinical, Hemodynamic, and Immunohistologic EMB-analysis of Intramyocardial Infiltration















n 17 17 23 23
LVEF (%) 19.0 ± 14.22 * 47.25 ± 12.27 31.3 ± 15.0 * 49.9 ± 12.4
LVEDD (mm) 56.23 ± 5.23 55.62 ± 8.43 56.43 ± 7.28 55.93 ± 4.29
TAPSE (mm) 20.48 ± 5.13 21.23 ± 5.34 21.96 ± 7.53 21.81 ± 6.33
IVSD (mm) 10.98 ± 3.15 10.42 ± 4.21 11.12 ± 3.15 11.02 ± 4.12
LVPW (mm) 10.14 ± 2.41 10.05 ± 2.24 10.25 ± 2.16 10.58 ± 2.07
NYHA I/II/III/VI 0/0/6/11 0/11/6/0 0/0/11/12 0/18/5/0
Immunohistologic Analysis
CD3+ T lymphocytes infiltration/mm2 397.3.4 ± 305.3 ** 23.57 ± 19.23 169.1 ± 111.5 ** 15.72 ± 17.94
LFA-1+ lymphocytes infiltration/mm2 612.6 ± 405.5 ** 40.91 ± 21.00 190.8 ± 119.6 * 23.77 ± 20.69
CD45R0+ T memory cells/mm2 584.5 ± 340.5 * 63.95 ± 59.47 208.1 ± 158.3 33.99 ± 25.62
perforin+ cytotoxic cells/mm2 21.70 ± 28.42 0.97 ± 0.72 39.22 ± 48.64 2.17 ± 4.73
Mac-1+ macrophages infiltration/mm2 569.3 ± 311.5 ** 59.44 ± 18.92 200.5 ± 111.3 ** 40.10 ± 26.42
Note: LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; TAPSE = tricuspid
annular plane systolic excursion; IVSD = intraventricular septum diameter; LVPW = left ventricular posterior wall;
NYHA = New York Heart Association Classification. Immunohistologic marker: CD3 = T-lymphocytes, LFA-1
= leukocyte function antigen-1, Mac-1 =macrophage-1 antigen, CD45R0 (UCHL1) = leucocyte common antigen,
perforin = cytotoxic cells. The data are presented as mean ± standard deviation, and as No. of subjects. Significant
variance between the value at baseline and after therapy are indicated (* p ≤ 0.05; ** p ≤ 0.01).
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The entire cohort of treated patients exhibited a significant improvement of LVEF (26.6 ± 15.6% to
48.9 ± 12.1%; p < 0.0001) following immunosuppressive treatment. Further subgroup analysis during the
follow-up to immunosuppressive treatment revealed a significant improvement of LVEF (19.0 ± 14.22% to
47.25 ± 12.27%; p = 0.0049) in patients (n = 17) whose GCs had been proved by histology, i.e., through
EMBs. Similarly, a significant increase of LVEF (31.3 ± 15.0% to 49.9± 12.4%; p = 0.0028) was also observed
at follow-up (see Figure 4) in those cases where the patient exhibited a positive myocardial gene profile
but where there was no direct histologic proof of multinuclear giant cells (n = 23).
Figure 4. Baseline and Follow-up Hemodynamic Outcomes After Immunosuppressive Therapy for
Patients with Histologically Proven or Gene-Profile-Detected IGCM. LVEF (%) was measured at baseline
and during the follow-up period. (A) All treated patients. (B) Patients with histologically proven
IGCM. (C) Patients with gene-profile-detected IGCM. The figures shown are mean values ± standard
deviation; P-values compared to the baseline EMB are indicated.
The improvement in LV function was accompanied by a reduction or complete absence of intramyocardial
inflammation in the follow-up EMB (Table 4). Only two patients were found to have persistent
inflammation. After extension of immunosuppressive therapy (>6 months), even these two patients
became immunohistologically negative. At the time of the baseline EMB, all the patients had presented
a specific pattern of deregulated genes relevant for IGCM. In the follow-up phase, the genes which had
been differentially expressed in the EMBs were found to have normalized, indicating that treatment
had been successful for 21 of the patients (90.0%) (Figure 5). Two patients who exhibited persistent
inflammation exhibited a gene profile that was still suggestive of IGCM. Immunosuppressive treatment
was therefore continued and the gene-expression values eventually normalized in accordance with
clinical and histologic parameters. None of the patients died during the observation.
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Figure 5. Analysis of Gene-Expression Dynamics Before and After Immunosuppressive Therapy of
Patients with Histologically Proven and Gene Profile-Detected IGCM. (A) The gene expression of
marker genes for IGCM were measured before and after applying immunosuppressive therapy and
were compared to a healthy control cohort in patients with normalized gene-expression profiles at
follow-up; the results indicated successful treatment. The mean expression for marker genes CPT1,
CCR6, CCR5, TLR8 and CCL20 normalized at follow-up and fell below a clinically relevant threshold
but did not reach the expression level of the control cohort. A dashed line indicates a clinically relevant
threshold for the specific gene expression. (B) and (C) The gene expression of marker genes observed in
two IGCM patients who exhibited persistent inflammation at follow-up along with a gene profile that
suggested persistence of GCs after treatment. P-values are denoted by asterisks: * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001, **** p ≤ 0.0001.
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4. Discussion
The main findings of this study are: (1) Of a selected panel of 27 genes previously identified to be
regulated in patients with IGCM, five genes (CPT1, CCL20, CCR5, CCR6, TLR8) are highly specific for
patients with IGCM compared with controls; (2) Our study suggests that by using this panel of five
genes, 54.3% of all IGCM cases would have been missed by using conventional histologic examination
alone; (3) Patients diagnosed with IGCM using this gene profile panel respond in a similar fashion
to immunosuppressive therapy as patients diagnosed with IGCM by conventional histology alone,
supporting the clinical utility of gene profiling in patients presenting with unexplained acute heart failure.
In this multicenter study, myocardial gene-expression profiling to diagnose IGCM was applied in
clinical practice for the first time, namely within a large cohort of patients suffering from unexplained
acute cardiac decompensation. This new gene-profiling approach significantly improves the diagnosis
rate for clinically suspected myocarditis and unexplained acute cardiac decompensation and helps to
identify GCs which would otherwise have been missed in a purely conventional, histological examination.
Our study population is unique in that it is by far one of largest group of IGCM patients ever evaluated.
Fraction of IGCM-positive patients as indicated by gene profile analysis was unexpectedly high as
suspected clinical diagnosis of IGCM was only assumed in 12 of 57 patients (21%) by the clinician.
Thanks to this new diagnostic test, moreover, giant-cell myocarditis is sure to be diagnosed more
widely going forward. This in turn will have dramatic prognostic and therapeutic relevance for patients.
After all, IGCM is the most aggressive form of active myocarditis and often has a fatal outcome. Thus,
there is a high medical need to detect IGCM as early as possible so as to avoid progressive myocardial
tissue damage, the eventual need for transplantation, or even cardiac death. It bears noting that, according
to various multicenter studies, the five-year transplant-free survival rate is no better than 10% [3,28–31].
The only way to directly confirm the presence of giant cells is to analyze histologic sections in the
form of EMBs [32], but that can be problematic [30,33]. Previous publications have postulated that
immunohistologic examinations of EMBs exhibit a high sensitivity because of the diffuse inflammatory
infiltration of cardiac tissue in IGCM [32]. Our study suggests, however, that there is a lack of sensitivity
relying solely on conventional histopathological analysis when investigating EMB for presence of
IGCM. This is where gene profiling, as a novel diagnostic tool, has several major advantages over
conventional EMB analysis. For one thing, the complete biopsy can be used for nucleic acid extraction.
For another, the results obtained from gene-expression profiling are more conclusive and less dependent
on the operator’s experience than those obtained from optical analysis.
Although immunosuppressive therapy is considered the mainstay of medical treatment for IGCM,
there is currently no consensus on how it should be executed; the optimal duration of treatment also
remains undefined [22]. Moreover, the taking of additional EMBs is often needed in order to confirm a
diagnosis, which can delay the initiation of treatment [22]. Also, the fulminant future course of the
disease is often not foreseeable at the time the EMB is taken, so that an IGCM diagnosis is not expected.
With gene-profiling, the repeated taking of EMBs could be avoided, immunosuppressive therapy could
be started immediately, and optimal treatment duration could be effectively monitored.
Interestingly, we were able to show that 23 of the 26 patients with histologically proven IGCM
exhibited active myocarditis according to the Dallas Classification. By contrast, active myocarditis
could be observed in only n = 6 of the patients who presented positive gene profiles for GCs but,
possibly due to the sampling error of histologic EMB analysis, presented no direct histologic proof of
GCs. Moreover, the levels of lymphocytic and macrophage infiltration were significantly higher in
patients who did exhibit histologic evidence of GCs than in patients who merely exhibited positive
gene profiles. Normally, no GCs would have been expected in the latter cases. It follows, therefore,
that the suspected diagnoses adopted by the clinicians must be viewed critically, given that they often
failed to even suspect IGCM. These observations underscore the risk posed by a sampling error and
the importance of new, supplementary diagnostic methods. One way to overcome these limitations
and the general sampling error of purely conventional histologic examination is to apply specific gene
J. Clin. Med. 2020, 9, 2689 12 of 15
profiling to look for indicators that multinucleated giant cells may be present in the human hearts
being examined [10,11,23].
Our study was furthermore able to demonstrate, using quantitative immunohistologic staining,
that the number of infiltrative cells in IGCM patients ranges widely. As expected, most patients
experience a massive increase in infiltrative cells. However, our data do show that there are also
patients with low inflammation and IGCM, possibly due to a focal inflammatory process. This may
explain the frequently faulty suspected diagnosis made by the clinician. We consider this observation
extremely important for clinicians and/or pathologists because the presence of a low inflammation in
the EMB should not become an exclusion criterion for IGCM.
Another aim of the present study was to show the efficacy of immunosuppressive treatment
in terms of achieving improved clinical outcomes and preventing a fatal course of IGCM [34–38].
Subgroup analysis of the clinical hemodynamic outcome of n = 40 GC patients undergoing immediate
immunosuppressive therapy revealed a significant improvement of LVEF at follow-up in those patients
whose GCs were proven by EMB histology. At the same time, EMB analysis revealed a significant
reduction in the quantified number of inflammatory infiltrates.
Similarly, a significant increase of LVEF after treatment was also observed in patients who exhibited
positive myocardial gene profiles for GCs. EMB analysis also revealed a significant reduction in the
quantified number of inflammatory infiltrates. These results underscore the clinical importance of our
gene-profiling analysis, for it allows the relevant, prognostic immunosuppressive therapy to be started
immediately, potentially a critical success factor. None of the patients in the overall patient cohort died
during the observation period.
5. Conclusions
Based on 427 examined patient samples, multinucleated giant cells could be detected in only 26
patients (6.1%) through the use of histology alone. When this was supplemented by gene profiling,
however, IGCM could be diagnosed in further 31 patients (7.2%), even in the absence of any direct
histologic proof of giant cells. This means that 54.3% of all IGCM cases would have been missed by
using conventional histologic examination alone. Which in turn highlights the importance of this new
diagnostic approach. Our results show that: (1) the evaluation of EMBs is essential in successfully
diagnosing IGCM, that (2) an analysis of gene-expression profiles in EMBs is of great clinical and
prognostic importance when it comes to compensating for the sampling error which occurs when
IGCM is diagnosed through a purely histologic examination of EMBs, and (3) patients diagnosed with
IGCM using this gene profile panel respond in a similar fashion to immunosuppressive therapy as
patients diagnosed with IGCM by conventional histology alone.
6. Limitations
This said, our study admittedly remains subject to certain caveats. For one thing, the limitations
typical for retrospective cohort studies apply to our analyses. These include, among other factors,
a lack of extended clinical data for all of the patients covered in this multicenter study. Furthermore,
the patients in our cohorts were mainly of Caucasian ethnicity (due to the location of our study centers),
which may possibly limit the applicability of our findings to other ethnic groups. On the other hand,
the validity of our results tends to be corroborated by the large number of cases investigated at the core
centers and by the fact that the histologic slides were independently reviewed by cardiac pathologists.
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CCL20 chemokine (C-C motif) ligand 20
CCR5 chemokine receptor 5
CCR6 chemokine receptor 6





EvG elastic van Gieson stain
GCs giant cells
IGCM idiopathic giant cell myocarditis
IVSD intraventricular septum diameter
LVEDD left ventricular end-diastolic diameter
LVEF left ventricular ejection fraction
LVPW left ventricular posterior wall
NYHA New York Heart Association Classification
RT-qPCR reverse transcription-quantitative polymerase chain reaction
TAPSE tricuspid annular plane systolic excursion
TLR8 toll-like receptor 8
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